Zhan-Ming Shi1
Xing-Bing Huang2,3
Yan-Ling Zhou2,3
Yu-Ping Ning2,3
Gabor S. Ungvari4,5
Yu-Tao Xiang6,7*
Wei Zheng2,3*- 1Department of Psychiatry, Chongqing Jiangbei Second Hospital, Chongqing Jiangbei Mental Health Center, Chongqing, China
- 2Department of Psychiatry, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, China
- 3Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical University, Guangzhou, China
- 4Section of Psychiatry, University of Notre Dame Australia, Fremantle, WA, Australia
- 5Division of Psychiatry, School of Medicine, University of Western Australia, Perth, WA, Australia
- 6Unit of Psychiatry, Department of Public Health and Medicinal Administration, & Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao, Macao SAR, China
- 7Centre for Cognitive and Brain Sciences, University of Macau, Macao, Macao SAR, China
A Correction on
Rapid treatment center for depression in China: constructive reflections and transnational implications
By Shi Z-M, Huang X-B, Zhou Y-L, Ning Y-P, Ungvari GS, Xiang Y-T and Zheng W (2025) Front. Psychiatry 16:1582312. doi: 10.3389/fpsyt.2025.1582312
A correction has been made to the section 3 Actionable recommendations, 3.1 Electroconvulsive therapy, Paragraph 1. The sentence previously stated:
“Because of its relatively moderate efficacy rate of approximately 60.0% (10) and known neurocognitive side effects (11), there are ongoing efforts aiming at refining the clinical application of ECT from various perspectives, including anesthetic selection, stimulation dosage, electrode placement and apnoeic oxygenation.”
The corrected sentence appears below:
“Because of its relatively moderate efficacy rate of 58% and 70%, for those with and without medication failure, respectively (10) and known neurocognitive side effects (11), there are ongoing efforts aiming at refining the clinical application of ECT from various perspectives, including anesthetic selection, stimulation dosage, electrode placement and apnoeic oxygenation.”
A correction has been made to the section 3 Actionable recommendations, 3.3 Magnetic seizure therapy, Paragraph 1. The sentence previously stated:
“Capitalizing on its advantageous profile of reduced neurocognitive side effects and comparable antidepressant efficacy to ECT (52), a team at Beijing Anding Hospital of Capital Medical University, have adopted an accelerated MST protocol termed daily MST, demonstrating rapid antidepressant effects (53).”
The corrected sentence appears below:
“Capitalizing on its advantageous profile of comparable antidepressant efficacy to ECT (52), a team at Beijing Anding Hospital of Capital Medical University have adopted an accelerated MST protocol termed daily MST, demonstrating rapid antidepressant effects (53).”
A correction has been made to the section 4 Discussion, 4.2 Comparisons of rapid antidepressant treatments, Paragraph 1. The sentences previously stated:
“A recent meta-analysis of six RCTs comparing the efficacy and safety of ECT with ketamine revealed no significant disparity between the two treatments (82). Conversely, another meta-analysis (83) concluded that ketamine, regardless of its administration route, surpassed ECT in effectiveness for MDD patients.”
The corrected sentences appear below:
“A recent meta-analysis supported the use of ECT over ketamine for inpatients (82). Conversely, another meta-analysis of RCTs comparing the efficacy of ECT with ketamine revealed no significant disparity between the two treatments (83).”
A correction has been made to the section 4 Discussion, 4.3 General/systemic deficiencies, Paragraph 2. The sentence previously stated:
“In rural regions, only 5.1% of patients with MDD received any healthcare treatment, compared to 8.9% in urban areas (89).”
The corrected sentence appears below:
“In rural regions, only 5.1% of patients with depressive disorders received any form of healthcare treatment, compared to 8.9% in urban areas (89).”
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: major depressive disorder, electroconvulsive therapy, ketamine, esketamine, esketamine nasal spray, magnetic seizure therapy, Stanford Neuromodulation Therapy, rapid treatment center
Citation: Shi Z-M, Huang X-B, Zhou Y-L, Ning Y-P, Ungvari GS, Xiang Y-T and Zheng W (2025) Correction: Rapid treatment center for depression in China: constructive reflections and transnational implications. Front. Psychiatry 16:1725742. doi: 10.3389/fpsyt.2025.1725742
Received: 15 October 2025; Accepted: 24 October 2025;
Published: 07 November 2025.
Edited and reviewed by:
Vassilis Martiadis, Asl Napoli 1 Centro, ItalyCopyright © 2025 Shi, Huang, Zhou, Ning, Ungvari, Xiang and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yu-Tao Xiang, eXR4aWFuZ0B1bS5lZHUubW8=; Wei Zheng, emhlbmd3ZWkwNzAyQDE2My5jb20=